Literature DB >> 34376581

Hsp90 Inhibitor STA9090 Sensitizes Hepatocellular Carcinoma to Hyperthermia-Induced DNA Damage by Suppressing DNA-PKcs Protein Stability and mRNA Transcription.

Lixia Liu1, Yaotang Deng1, Zhenming Zheng1, Zihao Deng1, Jinxin Zhang1, Jieyou Li1, Manfeng Liang1, Xueqiong Zhou1, Wenchong Tan1, Hongjun Yang2, Leonard M Neckers3, Fei Zou4, Xuemei Chen4.   

Abstract

As a conserved molecular chaperone, heat shock protein 90 (Hsp90) maintains the stability and homeostasis of oncoproteins and helps cancer cells survive. DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a pivotal role in the non-homologous end joining pathway for DNA double-strand breaks (DSB) repair. Tumor cells contain higher levels of DNA-PKcs to survive by the hostile tumor microenvironment and various antitumor therapies. Here, we showed that increased levels of Hsp90α, Hsp90β, and DNA-PKcs correlated with a poor overall survival in hepatocellular carcinoma (HCC). We revealed that Hsp90 N-terminal domain and C-terminal domain have different effects on DNA-PKcs protein and mRNA levels. The stability of DNA-PKcs depended on Hsp90α N-terminal nucleotide binding domain. Transcription factor SP1 regulates the transcription of PRKDC (gene name of DNA-PKcs) and is a client protein of Hsp90. Inhibition of Hsp90 N-terminal by STA9090 decreased the location of Hsp90α in nucleus, Hsp90α-SP1 interaction, SP1 level, and the binding of Hsp90α/SP1 at the proximal promoter region of PRKDC Because hyperthermia induces DSBs with increases level of DNA-PKcs, combined STA9090 treatment with hyperthermia effectively delayed the tumor growth and significantly decreased DNA-PKcs levels in xenografts model. Consistently, inhibition of Hsp90 increased the number of heat shock-induced γ-H2AX foci and delayed the repair of DSBs. Altogether, our results suggest that Hsp90 inhibitor STA9090 decreases DNA-PKcs protein stability and PRKDC mRNA level, which provide a theoretical basis for the promising combination therapy of hyperthermia and Hsp90 inhibitor in HCC. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34376581      PMCID: PMC8513797          DOI: 10.1158/1535-7163.MCT-21-0215

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.009


  45 in total

1.  Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.

Authors:  Anthone W Dunah; Hyunkyung Jeong; April Griffin; Yong-Man Kim; David G Standaert; Steven M Hersch; M Maral Mouradian; Anne B Young; Naoko Tanese; Dimitri Krainc
Journal:  Science       Date:  2002-05-02       Impact factor: 47.728

2.  Hsp90alpha recruited by Sp1 is important for transcription of 12(S)-lipoxygenase in A431 cells.

Authors:  Jan-Jong Hung; Chih-Ying Wu; Pao-Chi Liao; Wen-Chang Chang
Journal:  J Biol Chem       Date:  2005-08-23       Impact factor: 5.157

3.  Chromatin Immunoprecipitation (ChIP) of Heat Shock Protein 90 (Hsp90).

Authors:  Aneliya Yoveva; Ritwick Sawarkar
Journal:  Methods Mol Biol       Date:  2018

4.  Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma.

Authors:  Ying Jiang; Aihua Sun; Yang Zhao; Wantao Ying; Huichuan Sun; Xinrong Yang; Baocai Xing; Wei Sun; Liangliang Ren; Bo Hu; Chaoying Li; Li Zhang; Guangrong Qin; Menghuan Zhang; Ning Chen; Manli Zhang; Yin Huang; Jinan Zhou; Yan Zhao; Mingwei Liu; Xiaodong Zhu; Yang Qiu; Yanjun Sun; Cheng Huang; Meng Yan; Mingchao Wang; Wei Liu; Fang Tian; Huali Xu; Jian Zhou; Zhenyu Wu; Tieliu Shi; Weimin Zhu; Jun Qin; Lu Xie; Jia Fan; Xiaohong Qian; Fuchu He
Journal:  Nature       Date:  2019-02-27       Impact factor: 49.962

5.  Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2).

Authors:  Rathi N Pillai; Dean A Fennell; Vladimir Kovcin; Tudor-Eliade Ciuleanu; Rodryg Ramlau; Dariusz Kowalski; Michael Schenker; Ilker Yalcin; Florentina Teofilovici; Vojo M Vukovic; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2019-12-12       Impact factor: 44.544

6.  The Survival Benefit of Combination Therapy With Mild Temperature Hyperthermia and an Herbal Prescription of Gun-Chil-Jung in 54 Cancer Patients Treated With Chemotherapy or Radiation Therapy: A Retrospective Study.

Authors:  Hyeong Joon Jun; So-Jung Park; Hwi-Joong Kang; Ga-Young Lee; Namhun Lee; Ji Hye Park; Hwa-Seung Yoo
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

7.  A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes.

Authors:  Victoria Gillan; Kerry O'Neill; Kirsty Maitland; Francis M Sverdrup; Eileen Devaney
Journal:  PLoS Negl Trop Dis       Date:  2014-02-13

8.  Mild microwave ablation combined with HSP90 and TGF‑β1 inhibitors enhances the therapeutic effect on osteosarcoma.

Authors:  Lingling Chen; Ming Wang; Zefeng Lin; Mengyu Yao; Wanshun Wang; Shi Cheng; Binglin Li; Yu Zhang; Qingshui Yin
Journal:  Mol Med Rep       Date:  2020-05-22       Impact factor: 2.952

9.  Heat Shock Protein 90α-Dependent B-Cell-2-Associated Transcription Factor 1 Promotes Hepatocellular Carcinoma Proliferation by Regulating MYC Proto-Oncogene c-MYC mRNA Stability.

Authors:  Xueqiong Zhou; Ying Wen; Ye Tian; Meiling He; Xiangyu Ke; Zhizhou Huang; Yangfan He; Lixia Liu; Annette Scharf; Meiting Lu; Guowei Zhang; Yaotang Deng; Yuxia Yan; Matthias P Mayer; Xuemei Chen; Fei Zou
Journal:  Hepatology       Date:  2018-10-04       Impact factor: 17.425

Review 10.  Inhibitors of HSP90 in melanoma.

Authors:  Aleksandra Mielczarek-Lewandowska; Mariusz L Hartman; Malgorzata Czyz
Journal:  Apoptosis       Date:  2020-02       Impact factor: 4.677

View more
  1 in total

1.  Mistimed sleep and waking activity in humans disrupts glucocorticoid signalling transcripts and SP1, but not plasma cortisol rhythms.

Authors:  Simon N Archer; Carla S Möller-Levet; Emma E Laing; Derk-Jan Dijk
Journal:  Front Physiol       Date:  2022-08-17       Impact factor: 4.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.